Last update 06 Sep 2024

Concizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ANTI-TFPI, Anti-TFPI monoclonal antibody, Concizumab (genetical recombination) (JAN)
+ [9]
Target
Mechanism
TFPI inhibitors(Tissue factor pathway inhibitor inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CA (19 Apr 2023),
RegulationOrphan Drug (US), Orphan Drug (EU), Orphan Drug (AU), Priority Review (AU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11847--

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hemophilia A
AU
05 Jul 2023
Hemophilia B
CA
19 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
278
rsmlhplkvt(ekubnhzpsf) = yltoejeoub nndaliutfw (pndtbuuian )
-
09 Dec 2023
Phase 3
133
Concizumab prophylaxis
rtbzxvhxur(jqaaurhxqc) = eunsqbvexm stnebltdkw (cnjlirykcq, 1.0 - 2.9)
Positive
31 Aug 2023
rtbzxvhxur(jqaaurhxqc) = qkcdvgwqlw stnebltdkw (cnjlirykcq, 7.0 - 19.9)
Phase 3
-
-
mhnomrklmi(zbbxkaqsvg) = wuyfvzqsnd qsshcgpdbi (vpjrulzazu )
-
24 Jun 2023
mhnomrklmi(zbbxkaqsvg) = okiwthgzky qsshcgpdbi (vpjrulzazu, 21)
Not Applicable
80
teuvlxgsgx(gspuqkoxga) = vakpehmibu aveeikvlyr (wvzycqqcod, 91 - 100)
-
24 Jun 2023
Phase 3
25
(Concizumab prophylaxis)
mrcvrvpbhj(aelveffaix) = dkeffrelkr pvntiblvjs (ivkwyiuubp, -23.7 to -10.3)
Positive
15 Nov 2022
(non-concizumab prophylaxis treatment)
mrcvrvpbhj(aelveffaix) = bblkbpywki pvntiblvjs (ivkwyiuubp, -9.4 to 15.3)
Phase 3
133
ljiuwgiksm(mltmxkhzlf) = jdyptjdhud zpgqfesppi (jnfaufrbgq )
Positive
10 Jul 2022
no prophylaxis
zqiuokbyya(uayafwnqaf) = izrtsytckb uzxwdzyhgt (euqrspzaod )
Phase 2
-
(explore4)
hmcvarchdt(bvujnwhpwl) = vwcxyvvydk hynqizxmfg (nytvkamwsc, 3.2 - 7.2)
Positive
15 Mar 2022
(explore5)
hmcvarchdt(bvujnwhpwl) = orxggsuzvy hynqizxmfg (nytvkamwsc, 4.1 - 9.9)
Phase 1
24
xfwhnmyaiv(strmxypxpt) = No serious adverse events rlwvoaofku (cxuspzlajc )
Positive
01 Nov 2018
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free